Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fate Therapeutics launched through $14.6mm Series A

Executive Summary

Fate Therapeutics (adult stem cell biology) was recently launched through a two-tranche $14.6mm Series A round backed by Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, and Venrock. The start-up has a small-molecule platform that modulates adult stem cells to mimic the beneficial characteristics of embryonic stem cells.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies